F2 and COVID-19: Remdesivir is a direct-acting nucleotide prodrug inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase and treatment may lead to more rapid normalization of several biomarkers associated with COVID-19 severity, including ferritin, lactate dehydrogenase, prothrombin time, and lymphocyte count.25